In 2015, she co-founded Chase Medical Research of Greater New Haven and started to intensify the amount of her research activities. She is currently the sub-investigator for multi-institutional trials. This work started with a long-term outcome study to assess the effectiveness of adding an investigational drug to a multi-centre, randomized, double-blind, active-controlled, parallel group, phase III trial. The trial evaluated the safety, efficacy and comparison of add-on therapy with different doses of an investigational drug.
Extensive Research Description
In the area of cerebrovascular disease, Dr. Chustecki was involved in the following clinical trials:
1) A Randomized, Double Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin plus Aspirin to Aspirin alone in the Prevention of Reinfarction, Cardiovascular Death and Stroke in Post Myocardial Infarction Patient.
2) Evaluation of Autonomic Function by Heart Rate Variability in Patient with Mitral Valve Prolapse.
3) Correlation of Platelet Activation, Platelet PADGEM Expression during Percutaneus Transluminal Angioplasty with Rate of Early Restenosis.
4) Response to T-pa Therapy in Transgenic Mice with Human Apolipoprotein Measured by Nuclear Scan.
5) Establishing Value as a Lescol Usage and Treatment Efficacy – Investigator, Sponsored by Novartis Pharmaceutical Corporation, East Hanover, NJ.
6) Research on the Effects of Aceon Tablets in Hypertensive Subjects in a Community Trial - Investigator.
7) Cardiazem LA P.L.A.C.E. Program - Consultant.
Dr. Chustecki is currently the sub-investigator for multi-institutional trials:
1) A Long-Term Outcomes Study to assess the effectiveness of adding an investigational drug to statin therapy for patients with low levels of high-density lipoprotein-cholesterol (HDL-C) or high blood triglycerides and with a high risk for heart disease.
2) A Multi-Centre, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy and Comparison of Add-On Therapy of different doses of investigational drug in combination with Metformin in Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone.
3) A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of an investigational medication for treatment of Crohn's Disease.
4) A Randomized, Double-Blind, Parallel Group, Multi-Center Study to evaluate different doses of an investigational medication in patients with Moderate to Very Severe COPD.
5) An Open-Label, Long-Term Safety and Tolerability Study of new medication in Patients with Irritable Bowel Syndrome with Constipation (IBS-C).
6) A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of new drug Administered Intravenously in Patients with Migraines.
7) A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the new drug in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF).
8) A Multicenter Study Conducted to Evaluate the Performance of the new Test in Laboratory and Point of Care Testing Sites.